GRIP1 and myeloid sarcoma: Although this finding is internally consistent with well-documented neuroprotective effects of IFN-β in MS/EAE (Bermel and Rudick, 2007; Teige et al., 2003; Touil et al., 2006) and the role of GRIP1 in the type I IFN pathway (Flammer et al., 2010; Reily et al., 2006), a broader question regarding the type I IFN network in MS/EAE immunopathology remains unresolved.